Robert Samstein
YOU?
Author Swipe
View article: Mismatch repair deficiency drives malignant progression and alters the tumor immune microenvironment in glioblastoma models
Mismatch repair deficiency drives malignant progression and alters the tumor immune microenvironment in glioblastoma models Open
Mutations in DNA mismatch repair (MMR) pathway genes (MSH2, MSH6, MLH1, and PMS2) are linked to acquired resistance to temozolomide (TMZ) and high tumor mutation burden (TMB) in high-grade gliomas (HGG), including glioblastoma (GBM). Howev…
View article: Immunogenetics of cancer risk: an emerging role for HLA class II 2623
Immunogenetics of cancer risk: an emerging role for HLA class II 2623 Open
Description Host immune system contribution to cancer risk remains poorly understood and necessary to improve cancer prevention strategies. Detection of foreign antigens presented on MHC molecules is critical for immune recognition. Since …
View article: Defining the determinants of immune response in DNA homologous recombination deficient tumors 3797
Defining the determinants of immune response in DNA homologous recombination deficient tumors 3797 Open
Description Studies by our lab have demonstrated that DNA Damage Repair (DDR) pathways play a key role in determining response to ICB. To better characterize the effect of these alternations on the tumor immune microenvironment (TME) and d…
View article: Identifying targets of precancerous neoantigen-specific T cell surveillance in patients with Lynch syndrome and immune suppression programs supporting colorectal cancer progression 3671
Identifying targets of precancerous neoantigen-specific T cell surveillance in patients with Lynch syndrome and immune suppression programs supporting colorectal cancer progression 3671 Open
Description Pathogenic germline variants in mismatch repair (MMR) genes, or Lynch syndrome (LS), increases patients’ risk of developing colorectal cancer (CRC). We previously identified shared, frameshift (fs)-neoantigens in MMR deficient …
View article: PlanAct: An eclipse scripting API‐based module embedding clinical optimization strategies for automated planning in locally advanced non‐small cell lung cancer
PlanAct: An eclipse scripting API‐based module embedding clinical optimization strategies for automated planning in locally advanced non‐small cell lung cancer Open
Background Manual intensity‐modulated radiotherapy (IMRT) planning for locally advanced non‐small cell lung cancer (LA‐NSCLC) is labor‐intensive and time‐consuming. Knowledge‐based planning (e.g., RapidPlan) improves consistency but common…
View article: The Role of Immunotherapy and Radiation Therapy in the Treatment of Breast Cancer
The Role of Immunotherapy and Radiation Therapy in the Treatment of Breast Cancer Open
Breast cancer is the most commonly diagnosed non-cutaneous cancer and is the leading cause of cancer mortality in females worldwide. Breast cancer incidence has been increasing over the last few decades; simultaneously, novel therapeutic a…
View article: Impact of Normal Lung Volume Choices on Radiation Pneumonitis Risk Prediction in Locally Non-small Cell Lung Cancer Radiation Therapy
Impact of Normal Lung Volume Choices on Radiation Pneumonitis Risk Prediction in Locally Non-small Cell Lung Cancer Radiation Therapy Open
In line with previous studies, both statistical analysis and SHAP interpretation confirmed that V20 and MLD were associated with RP2. The machine learning models indicated that defining normal lung volume as TL-PTV yielded the highest pred…
View article: Transforming Brain Tumor Care: The Global Impact of Radiosurgery in Multidisciplinary Treatment Over Two Decades
Transforming Brain Tumor Care: The Global Impact of Radiosurgery in Multidisciplinary Treatment Over Two Decades Open
Background Stereotactic radiosurgery, a minimally invasive treatment delivering high doses of radiation to a well‐defined target, has transformed interdisciplinary treatment paradigms since its inception. This study chronicles its adoption…
View article: Coordinated macrophage and T cell interactions mediate response to checkpoint blockade in colorectal cancer
Coordinated macrophage and T cell interactions mediate response to checkpoint blockade in colorectal cancer Open
Summary Mismatch repair deficiency (MMRd), either due to inherited or somatic mutation, is prevalent in colorectal cancer (CRC) and other cancers. While anti-PD-1 therapy is utilized in both local and advanced disease, up to 50% of MMRd CR…
View article: Impact of normal lung volume choices on radiation pneumonitis risk prediction in locally advanced NSCLC radiotherapy
Impact of normal lung volume choices on radiation pneumonitis risk prediction in locally advanced NSCLC radiotherapy Open
This study is to evaluate the impact of lung volume choices on predicting radiation pneumonitis (RP) risk in patients with locally advanced NSCLC undergoing radiotherapy. Dosimetric variables V20, V5, and mean lung dose (MLD) were extracte…
View article: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial Open
Cystectomy is a standard treatment for muscle-invasive bladder cancer (MIBC), but it is life-altering. We initiated a phase 2 study in which patients with MIBC received four cycles of gemcitabine, cisplatin, plus nivolumab followed by clin…
View article: The incorporation of cognitive-sparing techniques into prophylactic cranial irradiation in the management of small cell lung cancer
The incorporation of cognitive-sparing techniques into prophylactic cranial irradiation in the management of small cell lung cancer Open
The use of prophylactic cranial irradiation (PCI) remains an important component in the management of small cell lung cancer (SCLC). This is due to the high rates of subclinical brain metastases at the time of diagnosis. Following a respon…
View article: Radiotherapy and Immunotherapy in Lung Cancer
Radiotherapy and Immunotherapy in Lung Cancer Open
The emergence of immune checkpoint inhibitors (ICIs) as a pillar of cancer treatment has emphasized the immune system’s integral role in tumor control and progression through cancer immune surveillance. ICIs are being investigated and inco…
View article: Figure S1 from Genomic Determinants of Clinical Outcomes in Rhabdomyosarcoma
Figure S1 from Genomic Determinants of Clinical Outcomes in Rhabdomyosarcoma Open
Tumor mutational age (TMB) by age (p=0.58 for fusion-negative patients, Pearson coefficient = -0.07, R2 = 0.005; and p=0.04 for fusion-positive patients, Pearson coefficient = 0.44, R2 = 0.20)
View article: Supplementary Data from Genomic Determinants of Clinical Outcomes in Rhabdomyosarcoma
Supplementary Data from Genomic Determinants of Clinical Outcomes in Rhabdomyosarcoma Open
Supplementary Figure Legends
View article: Data from Genomic Determinants of Clinical Outcomes in Rhabdomyosarcoma
Data from Genomic Determinants of Clinical Outcomes in Rhabdomyosarcoma Open
Purpose:Increased availability of next-generation sequencing has allowed for the genomic characterization of a variety of pediatric tumors, although genomic determinants of response to treatment remain largely unknown. We sought to evaluat…
View article: Figure S1 from Genomic Determinants of Clinical Outcomes in Rhabdomyosarcoma
Figure S1 from Genomic Determinants of Clinical Outcomes in Rhabdomyosarcoma Open
Tumor mutational age (TMB) by age (p=0.58 for fusion-negative patients, Pearson coefficient = -0.07, R2 = 0.005; and p=0.04 for fusion-positive patients, Pearson coefficient = 0.44, R2 = 0.20)
View article: Figure S2 from Genomic Determinants of Clinical Outcomes in Rhabdomyosarcoma
Figure S2 from Genomic Determinants of Clinical Outcomes in Rhabdomyosarcoma Open
TP53 mutational status by age (p=0.05)
View article: Data from Genomic Determinants of Clinical Outcomes in Rhabdomyosarcoma
Data from Genomic Determinants of Clinical Outcomes in Rhabdomyosarcoma Open
Purpose:Increased availability of next-generation sequencing has allowed for the genomic characterization of a variety of pediatric tumors, although genomic determinants of response to treatment remain largely unknown. We sought to evaluat…
View article: Supplementary Data from Genomic Determinants of Clinical Outcomes in Rhabdomyosarcoma
Supplementary Data from Genomic Determinants of Clinical Outcomes in Rhabdomyosarcoma Open
Supplementary Figure Legends